GlassScriptPhysician profile
Michelle B Deshazer
NPI 1295013795
$12,907.49
in general payments reported to CMS, 2019-2025
24 companies · $2,987 in 2025
The $2,987 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,746 · 2022: $3,029 · 2023: $3,179 · 2024: $1,968 · 2025: $2,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,171 · Education: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,171.24 |
| Education | $961.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,192.40 | 2021-2025 | |
| Janssen Biotech, INC. | $1,407.85 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $1,307.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,044.16 | 2021-2025 | Dupixent |
| Pfizer INC. | $1,007.27 | 2021-2025 | |
| Lilly USA, LLC | $808.63 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $804.70 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $773.35 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $655.45 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $568.30 | 2021-2025 | |
| Ucb, INC. | $481.12 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $457.13 | 2023-2025 | Zoryve |
| Incyte Corporation | $395.66 | 2021-2025 | Opzelura |
| Amgen INC. | $317.10 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $214.42 | 2024-2025 | Nemluvio, Aklief |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $135.66 | 2023-2024 | Vtama |
| Organon LLC | $89.32 | 2025 | Vtama |
| Biofrontera INC. | $65.67 | 2021-2022 | |
| Almirall LLC | $50.43 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.23 | 2021-2025 | Siliq, Duobrii |
| Helsinn Therapeutics (U.S.), INC. | $34.66 | 2021-2022 | |
| Sandoz INC. | $20.81 | 2024 | Hyrimoz |
| Vyne Pharmaceuticals INC. | $17.95 | 2021 | |
| Genentech USA, INC. | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Deshazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.